ScienceMed®

Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial

Oncologia
Imagem de arquivo, ilustrativa — não é do estudo. Tecido hepático humano ao microscópio óptico, coloração HE. Mikael Häggström · CC0 · Wikimedia Commons

Ensaio clínico randomizadoNível 2 · Nova evidênciaThe oncologist5 fev 20261 citações

Salvar

Resumo original em inglês

O que aconteceu

Chemotherapy-induced nausea and vomiting (CINV) significantly impact the patients' quality of life. Whether the granisetron transdermal delivery system (GTDS) offers better protection than palonosetron against long-delayed (120-168 hours) CINV after highly or moderately emetogenic chemotherapy (HEC/MEC) had not been prospectively tested.

A multicenter, randomized clinical study was conducted in China. Patients scheduled to receive either HEC or MEC were randomly assigned (1:1) to GTDS or palonosetron, each in combination with a neurokinin-1 receptor antagonist (NK1-RA) and dexamethasone. The primary endpoint was the complete response (CR; no vomiting and no rescue medication) rate during the long-delayed phase (120-168 hours), stratified by HEC and MEC categories, to demonstrate the superiority of GTDS over palonosetron.

Clinicaltrials.gov Identifier: NCT04912271 (in-house ethic number: YBCSG-21-04).

O que encontraram

Overall, 150 patients received either GTDS or palonosetron respectively. We found that the GTDS group demonstrated a significantly higher long-delayed CR rate (97.3%) than the palonosetron group (92%) (P = .04). This advantage was driven predominantly by the HEC subgroup (GTDS 97.5% vs palonosetron 90.8%, P = .028). No significant differences were observed between the groups for the acute (0-24 hours, 92.7% vs 90.0%; P = .412), delayed (24-120 hours, 80.0% vs 76.0%; P = .403), extended-delayed (24-168 hours, 80.7% vs 75.3%; P = .265), or overall (0-168 hours, 78.0% vs 74.0%; P = .417) phases.

Por que isso importa

A GTDS-based triple antiemetic regimen can effectively control CINV associated with HEC or MEC. It provides a convenient alternative route for delivering granisetron for up to 7 days, with superior efficacy in controlling long-delayed CINV.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.

O estudo original

Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial

Xiaojun Liu, Yanchun Meng, Yiqun Du, Yuxin Mu, Gang Li, Hengyu Li, Xiaoxiang Guan, Jian Zhang

Descritores MeSH

  • Palonosetron
  • Antiemetics
  • Nausea
  • Neoplasms
  • Vomiting
  • Granisetron
  • Female
  • Humans
  • Isoquinolines
  • Male

Veja também

Estudos relacionados